Working… Menu
Trial record 1 of 1 for:    NCT03501979
Previous Study | Return to List | Next Study

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03501979
Recruitment Status : Active, not recruiting
First Posted : April 18, 2018
Last Update Posted : October 14, 2021
Translational Breast Cancer Research Consortium
Johns Hopkins University
Seagen Inc.
University of Michigan
Georgetown University
University of California, San Francisco
University of Chicago
Indiana University
University of Washington
University of Texas
Information provided by (Responsible Party):
Erica Stringer-Reasor, University of Alabama at Birmingham

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 22, 2021
Estimated Study Completion Date : September 2023